M3 Financials

MTHRF Stock  USD 9.45  1.12  13.45%   
You can make use of M3 Inc fundamental data analysis to find out if markets are at this moment mispricing the company. We were able to interpolate data for thirty-six available financial indicators for M3, which can be compared to its peers in the sector. The stock experiences a very speculative upward sentiment. The trend is possibly hyped up. Check odds of M3 to be traded at $11.81 in 90 days.
  

M3 Stock Summary

M3 competes with Definitive Healthcare, Privia Health, and HealthStream. M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet. M3, Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan. M3 operates under Health Information Services classification in the United States and is traded on OTC Exchange. It employs 9384 people.
InstrumentUSA Pink Sheet View All
ExchangePINK Exchange
Business AddressAkasaka Intercity, Tokyo,
SectorHealthcare
IndustryHealth Information Services
BenchmarkDow Jones Industrial
Websitecorporate.m3.com
Phone81 3 6229 8900
CurrencyUSD - US Dollar

M3 Key Financial Ratios

There are many critical financial ratios that M3's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that M3 Inc reports annually and quarterly.

M3 Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining M3's current stock value. Our valuation model uses many indicators to compare M3 value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across M3 competition to find correlations between indicators driving M3's intrinsic value. More Info.
M3 Inc is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about  0.70  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for M3 Inc is roughly  1.43 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the M3's earnings, one of the primary drivers of an investment's value.

M3 Inc Systematic Risk

M3's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. M3 volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-one with a total number of output elements of fourty. The Beta measures systematic risk based on how returns on M3 Inc correlated with the market. If Beta is less than 0 M3 generally moves in the opposite direction as compared to the market. If M3 Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one M3 Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of M3 is generally in the same direction as the market. If Beta > 1 M3 moves generally in the same direction as, but more than the movement of the benchmark.

M3 February 18, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of M3 help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of M3 Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of M3 Inc based on widely used predictive technical indicators. In general, we focus on analyzing M3 Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build M3's daily price indicators and compare them against related drivers.

Complementary Tools for M3 Pink Sheet analysis

When running M3's price analysis, check to measure M3's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy M3 is operating at the current time. Most of M3's value examination focuses on studying past and present price action to predict the probability of M3's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move M3's price. Additionally, you may evaluate how the addition of M3 to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Fundamental Analysis
View fundamental data based on most recent published financial statements
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume